查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1516329

癌症基因治疗市场-按类型（体外、体内）、治疗（溶瘤病毒疗法、基因诱导免疫疗法、基因转移）、产品（病毒载体{腺病毒、慢病毒}、非病毒载体）、最终用途, 全球预测（2024 - 2032）

Cancer Gene Therapy Market - By Type (Ex-vivo, In-vivo), Therapy (Oncolytic Virotherapy, Gene-induced Immunotherapy, Gene Transfer), Product (Viral Vectors {Adenoviruses, Lentiviruses}, Non-viral Vectors), End-use, Global Forecast (2024 - 2032)
出版日期: | 出版商: Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3个工作天内

价格
简介目录

由于全球癌症盛行率不断增加，癌症基因治疗市场规模预计在 2024 年至 2032 年间将以 20.5% 的复合年增长率扩大。基因工程和生物技术的巨大进步正在促进有效基因疗法的开发。製药公司和政府措施不断增加的投资进一步支持研究和临床试验。

根据美国癌症协会的资料，预计2024年美国将新增2,001,140例癌症病例。人们越来越认识到基因疗法在分子层面上针对癌症的潜力，这增加了其巨大的吸引力。递送系统的创新发展和持续的临床成功正在增强基因治疗的可信度和兴趣，从而促进市场成长。

整个产业分为类型、疗法、产品、最终用途和地区。

根据类型，由于其高精度和有效性，到 2032 年，体外部分预计将在癌症基因治疗市场中占据相当大的份额。离体疗法允许在体外修改患者细胞，以确保有针对性和受控的基因改变。细胞培养技术的进步和改进的输送机制正在提高功效。临床试验成功率的不断提高以及对个人化癌症治疗的需求不断增长正在加速该细分市场的成长。

就最终用途而言，由于癌症研究的资金和投资不断增加，预计从 2024 年到 2032 年，研究机构领域的癌症基因治疗产业规模将大幅成长。领先的研究机构专注于创新基因治疗技术的开发、增进科学理解并进行临床试验。与製药公司的合作和政府的支持也加速了这些疗法在研究机构中的采用。

从地区来看，由于该地区癌症盛行率不断上升以及人们对先进治疗的认识不断增强，预计亚太地区癌症基因治疗产业将在 2024 年至 2032 年间取得实质进展。政府措施和资金的启动正在支持基因治疗的研发。生物技术和基因工程的进步正在提高治疗效果。当地研究机构与全球製药公司之间的创新合作将有利于区域市场的成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 不断增加的研发投资和对新型癌症疗法的需求
      • 基因治疗的技术进步
      • 癌症发生率增加
      • 产品核准和上市数量不断增加
    • 产业陷阱与挑战
      • 治疗费用高
  • 成长潜力分析
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 竞争定位矩阵
  • 战略仪錶板

第 5 章：市场估计与预测：按类型，2021 - 2032

  • 主要趋势
  • 离体
  • 体内

第 6 章：市场估计与预测：按疗法分类，2021 - 2032 年

  • 主要趋势
  • 溶瘤病毒疗法
  • 基因诱导的免疫治疗
  • 基因转移

第 7 章：市场估计与预测：按产品分类，2021 - 2032 年

  • 主要趋势
  • 病毒载体
    • 腺病毒
    • 慢病毒
    • 逆转录病毒
    • 腺相关病毒
    • 单纯疱疹病毒
    • 牛痘病毒
    • 其他病毒载体
  • 非病毒载体
  • 其他产品

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

  • 主要趋势
  • 生物製药公司
  • 研究机构
  • 其他最终用户

第 9 章：市场估计与预测：按地区，2021 - 2032

  • 主要动向：按地区
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 亚太地区其他地区
  • 世界其他地区

第 10 章：公司简介

  • Abeona Therapeutics Inc.
  • Altor Bioscience Inc.
  • Asklepios BioPharmaceutical Inc.
  • Bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Elevate Bio
  • Genelux Corporation
  • GlaxoSmithKline Inc.
  • Introgen Therapeutics Inc.
  • Merck KGaA
  • Novartis AG
简介目录
Product Code: 763

Cancer Gene Therapy Market size is projected to expand at 20.5% CAGR between 2024 and 2032, owing to the increasing prevalence of cancer worldwide. Strong advances in genetic engineering and biotechnology are facilitating the development of effective gene therapies. The growing investments from pharmaceutical companies and government initiatives are further supporting research and clinical trials.

According to data from the American Cancer Society, the U.S. is estimated to have 2,001,140 new cancer cases in 2024. The rising preference of patients for personalized medicine is driving the demand for gene therapy for cancer treatment. The growing awareness about the potential of gene therapy to target cancer at the molecular level is adding to its high appeal. Innovative developments in delivery systems and the ongoing clinical successes are bolstering the credibility and interest in gene therapy, adding to the market growth.

The overall industry is segregated into type, therapy, product, end-use, and region.

Based on type, the ex-vivo segment is projected to account for sizeable share of the cancer gene therapy market by 2032, owing to its high precision and effectiveness. Ex-vivo therapy allows the modification of patient cells outside the body for ensuring targeted and controlled genetic alterations. The advances in cell culture technologies and improved delivery mechanisms are improving efficacy. The increasing success rates in clinical trials and the growing demand for personalized cancer treatments are accelerating the segment growth.

In terms of end-use, the cancer gene therapy industry size from the research institutes segment is estimated to grow at significant rate from 2024 to 2032, due to the increasing funding and investments in cancer research. Leading research institutes are focusing on the development of innovative gene therapy techniques, advancing scientific understanding, and conducting clinical trials. The collaboration with pharmaceutical companies and government support are also accelerating the adoption of these therapies in research institutes.

Regionally, the Asia Pacific cancer gene therapy industry is projected to depict substantial gains between 2024 and 2032, on account of the rising cancer prevalence and increasing awareness of advanced treatments in the region. The launch of government initiatives and funding are supporting R&D in gene therapy. The advances in biotechnology and genetic engineering are enhancing treatment efficacy. The collaborations between local research institutes and global pharmaceutical companies for innovations will favor the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising R&D investments and demand for novel cancer therapeutics
      • 3.2.1.2 Technological advancements in gene therapy
      • 3.2.1.3 Increasing incidence of cancer
      • 3.2.1.4 Increasing number of product approvals and launches
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of therapy
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Million)

  • 5.1 Key trends
  • 5.2 Ex-vivo
  • 5.3 In-vivo

Chapter 6 Market Estimates and Forecast, By Therapy, 2021 - 2032 ($ Million)

  • 6.1 Key trends
  • 6.2 Oncolytic virotherapy
  • 6.3 Gene-induced immunotherapy
  • 6.4 Gene transfer

Chapter 7 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Million)

  • 7.1 Key trends
  • 7.2 Viral vectors
    • 7.2.1 Adenoviruses
    • 7.2.2 Lentiviruses
    • 7.2.3 Retrovirus
    • 7.2.4 Adeno associated virus
    • 7.2.5 Herpes simplex virus
    • 7.2.6 Vaccinia virus
    • 7.2.7 Other viral vectors
  • 7.3 Non-viral vectors
  • 7.4 Other products

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Million)

  • 8.1 Key trends
  • 8.2 Biopharma companies
  • 8.3 Research institutes
  • 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

  • 9.1 Key trends, by region
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 Rest of Asia Pacific
  • 9.5 Rest of the World

Chapter 10 Company Profiles

  • 10.1 Abeona Therapeutics Inc.
  • 10.2 Altor Bioscience Inc.
  • 10.3 Asklepios BioPharmaceutical Inc.
  • 10.4 Bluebird bio, Inc.
  • 10.5 Bristol-Myers Squibb Company
  • 10.6 Elevate Bio
  • 10.7 Genelux Corporation
  • 10.8 GlaxoSmithKline Inc.
  • 10.9 Introgen Therapeutics Inc.
  • 10.10 Merck KGaA
  • 10.11 Novartis AG